Essais liés11clinical trials
VilleLeidenlocalisation
PaysNetherlandslocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT06392386

Ouvrir le site du centre

Essais cliniques associés

11
MoléculeIndication / populationPhaseNCTTitreStatut
PreciseOnco — Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance Cancer À vérifier NCT07636148 PreciseOnco — Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance RECRUITING
BBP-418 (ribitol) Myopathies Phase 3 NCT05775848 Fortify — Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I) ACTIVE_NOT_RECRUITING
Efgartigimod PH20 SC Myasthénie Phase 2/3 NCT06392386 ADAPT Jr SC — A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis RECRUITING
K+ in CKD — Potassium Supplementation in CKD Hypertension Non applicable NCT03253172 K+ in CKD — Potassium Supplementation in CKD ACTIVE_NOT_RECRUITING
CAPTURE - MG — Capturing Key MG-symptoms Using Smartphone Recordings. Myasthénie À vérifier NCT06743490 CAPTURE - MG — Capturing Key MG-symptoms Using Smartphone Recordings. RECRUITING
FIT to ACT-MG — Interventions Against Fatigue in Patients With Myasthenia Gravis Myasthénie Non applicable NCT06659627 FIT to ACT-MG — Interventions Against Fatigue in Patients With Myasthenia Gravis ACTIVE_NOT_RECRUITING
Nipocalimab Myasthénie Phase 2/3 NCT05265273 A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis RECRUITING
Efgartigimod IV Myasthénie Phase 3 NCT06298552 ADAPT SERON — A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis ACTIVE_NOT_RECRUITING
Pyridostigmine Myasthénie Phase 3 NCT05919407 IMPACT-MG — Pyridostigmine and Amifampridine for Myasthenia Gravis UNKNOWN
Drisapersen Myopathies À vérifier NCT02636686 Extension Study of Drisapersen in DMD Subjects NO_LONGER_AVAILABLE
BMN 044 IV 6 mg/kg Myopathies Phase 2 NCT02958202 Extension Study of BMN 044 in Duchenne Muscular Dystrophy (DMD) TERMINATED